321309-38-0 Usage
General Description
3,4-Dihydro-2H-1,5-benzodioxepine-7-sulfonyl chloride is a chemical compound used as a building block in organic synthesis. It belongs to the class of sulfonyl chlorides and is commonly used in the pharmaceutical industry to introduce the sulfonyl group into molecules, which can impart desirable pharmacological properties. 3,4-DIHYDRO-2H-1,5-BENZODIOXEPINE-7-SULFONYL CHLORIDE is also utilized in the synthesis of various pharmaceuticals and agrochemicals. Its reactivity as a sulfonyl chloride makes it a versatile intermediate in the preparation of a wide range of organic compounds. Additionally, it is known for its potential as a reagent in chemical reactions such as sulfonylation and other transformations in organic synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 321309-38-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,1,3,0 and 9 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 321309-38:
(8*3)+(7*2)+(6*1)+(5*3)+(4*0)+(3*9)+(2*3)+(1*8)=100
100 % 10 = 0
So 321309-38-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H9ClO4S/c10-15(11,12)7-2-3-8-9(6-7)14-5-1-4-13-8/h2-3,6H,1,4-5H2
321309-38-0Relevant articles and documents
Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
-
Page/Page column 17; 24, (2010/11/25)
Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.